Novel psychoactive substances (NPS) – knowledge and experiences of drug users from Hungary, Poland, the UK and the USA

Pisarska, Agnieszka, Deluca, Paolo, Demetrovics, Zsolt, Corkery, John, Moskalewicz, Jacek, ReDNet Group, Corazza, Ornella, Corkery, John, Stair, Jacqueline, Fergus, Suzanne, Pezzolesi, Cinzia and Schifano, Fabrizio (2020) Novel psychoactive substances (NPS) – knowledge and experiences of drug users from Hungary, Poland, the UK and the USA. Neuropsychopharmacologia Hungarica, 21 (3). pp. 152-163. ISSN 1419-8711
Copy

Dopamine D 3 receptor partial agonists represent a new generation of atypical antipsychotics. Cariprazine, which has received centralized market authorization from the European Medicines Agency in 2017 for the treatment of adult patients with schizophrenia (including those with predominant negative symptoms of schizophrenia) differs from the other two partial agonist antipsychotics aripiprazole and brexpiprazole due to its unique features. Cariprazine is a dopamine D 3 preferring D 3/D2 partial agonist with very similar dopamine receptor sub-type selectivity as dopamine. It has proven efficacy in the treatment of positive and negative symptoms of schizophrenia, as well as for relapse prevention. Further phase-3 clinical studies proved the efficacy of cariprazine in the acute treatment of manic or mixed episodes associated with bipolar I disorder, as well as in bipolar depression. For the adjunctive treatment of major depressive disorder, phase 3 studies are in progress.
Item Type Article
Additional information Funding Information: This publication arises from the activities of the RedNet Research Project which have received funding from the EU in the framework of the Public Health Programme (2009 12 16). Zsolt Demetrovics acknowledges the support of the Hungarian National Research, Development and Innovation Office (Grant numbers: K111938, KKP126835). Funding Information: Acknowledgment: This publication arises from the activities of the RedNet Research Project which have received funding from the EU in the framework of the Public Health Programme (2009 12 16). Zsolt Demetrovics acknowledges the support of the Hungarian National Research, Development and Innovation Office (Grant numbers: K111938, KKP126835). Publisher Copyright: © 2019, Hungarian Association of Psychopharmacology. All rights reserved.
Keywords novel psychoactive substances, drugs, addiction, delegalisation, international study, predominant negative symptoms, atypical antipsychotic, cariprazine, schizophrenia, dopamine d and d receptor partial agonist, clinical neurology, neuropsychology and physiological psychology, general neuroscience, pharmacology, toxicology and pharmaceutics(all)
Date Deposited 15 May 2025 14:13
Last Modified 31 May 2025 00:23

Explore Further

picture_as_pdf
v21i4p152.pdf
subject
Published Version
copyright
Available under Unspecified
View Download
visibility_off description
Submitted Version
lock

Atom BibTeX OpenURL ContextObject in Span OpenURL ContextObject Dublin Core MPEG-21 DIDL Data Cite XML EndNote HTML Citation METS MODS RIOXX2 XML Reference Manager Refer ASCII Citation
Export

Downloads